ABSTRACT
Systemic sclerosis (SSc) is a rare connective tissue disease of unknown etiology characterized by chronic inflammation and fibrosis of the skin, vascular abnormalities, and variable involvement of organs including kidneys, gastrointestinal tract, heart, and lungs. SSc shows a complex etiology in which both environmental and genetic factors seem to influence the onset and outcome of the disease. We provide an extensive overview of the genetic factors and epigenetic modifications and what their knowledge has revealed in terms of etiopathogenesis of SSc.
Subject(s)
Scleroderma, Systemic/genetics , B-Lymphocytes/immunology , Epigenesis, Genetic , Humans , Interleukin-12/immunology , Scleroderma, Systemic/immunology , T-Lymphocytes/immunology , Tumor Necrosis Factor-alpha/immunologyABSTRACT
INTRODUCTION: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, and may be administered off-label to treat disseminated granuloma annulare systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. AREAS COVERED: infliximab and adalimumab can induce the development of anti-infliximab (anti-IFX) and anti-adalimumab (anti-ADA) monoclonal antibodies (mAbs). In this review, we discuss the impact of anti-IFX and anti-ADA mAbs upon efficacy and safety of these biological agents. EXPERT OPINION: IgG/IgE neutralizing antibodies against infliximab and adalimumab decrease the possibility of achieving a minimal disease activity state or clinical remission, decrease drug survival, increase the need for doctors to prescribe a higher drug dosage and, finally, favor the occurrence of adverse events. Concomitant administration of DMARDs such as methotrexate or leflunomide prevents the development of neutralizing Abs against infliximab and adalimumab.
Subject(s)
Adalimumab/immunology , Antirheumatic Agents/immunology , Infliximab/immunology , Adalimumab/administration & dosage , Adalimumab/adverse effects , Antibodies, Monoclonal/immunology , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Dose-Response Relationship, Drug , Humans , Hypersensitivity, Delayed/immunology , Immune System Diseases/drug therapy , Immune System Diseases/immunology , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Infliximab/administration & dosage , Infliximab/adverse effects , Receptors, Tumor Necrosis Factor/antagonists & inhibitorsABSTRACT
Diabetes insipidus is a disease in which large volumes of dilute urine (polyuria) are excreted due to vasopressin (AVP) deficiency [central diabetes insipidus (CDI)] or to AVP resistance (nephrogenic diabetes insipidus). In the majority of patients, the occurrence of CDI is related to the destruction or degeneration of neurons of the hypothalamic supraoptic and paraventricular nuclei. The most common and well recognized causes include local inflammatory or autoimmune diseases, vascular disorders, Langerhans cell histiocytosis (LCH), sarcoidosis, tumors such as germinoma/craniopharyngioma or metastases, traumatic brain injuries, intracranial surgery, and midline cerebral and cranial malformations. Here we have the opportunity to describe an unusual case of female patient who developed autoimmune CDI following ureaplasma urealyticum infection and to review the literature on this uncommon feature. Moreover, we also discussed the potential mechanisms by which ureaplasma urealyticum might favor the development of autoimmune CDI.
Subject(s)
Female , Humans , Middle Aged , Arthritis, Reactive/immunology , Autoimmune Diseases/microbiology , Diabetes Insipidus, Neurogenic/microbiology , Ureaplasma urealyticum , Ureaplasma Infections/immunology , Autoantibodies , Arthritis, Reactive/microbiology , Autoimmune Diseases/etiology , Diabetes Insipidus, Neurogenic/etiology , Diabetes Insipidus, Neurogenic/immunology , Neurophysins/immunology , Protein Precursors/immunology , Ureaplasma Infections/complications , Vasopressins/immunologyABSTRACT
Diabetes insipidus is a disease in which large volumes of dilute urine (polyuria) are excreted due to vasopressin (AVP) deficiency [central diabetes insipidus (CDI)] or to AVP resistance (nephrogenic diabetes insipidus). In the majority of patients, the occurrence of CDI is related to the destruction or degeneration of neurons of the hypothalamic supraoptic and paraventricular nuclei. The most common and well recognized causes include local inflammatory or autoimmune diseases, vascular disorders, Langerhans cell histiocytosis (LCH), sarcoidosis, tumors such as germinoma/craniopharyngioma or metastases, traumatic brain injuries, intracranial surgery, and midline cerebral and cranial malformations. Here we have the opportunity to describe an unusual case of female patient who developed autoimmune CDI following ureaplasma urealyticum infection and to review the literature on this uncommon feature. Moreover, we also discussed the potential mechanisms by which ureaplasma urealyticum might favor the development of autoimmune CDI.
Subject(s)
Arthritis, Reactive/immunology , Autoimmune Diseases/microbiology , Diabetes Insipidus, Neurogenic/microbiology , Ureaplasma Infections/immunology , Ureaplasma urealyticum , Arthritis, Reactive/microbiology , Autoantibodies , Autoimmune Diseases/etiology , Diabetes Insipidus, Neurogenic/etiology , Diabetes Insipidus, Neurogenic/immunology , Female , Humans , Middle Aged , Neurophysins/immunology , Protein Precursors/immunology , Ureaplasma Infections/complications , Vasopressins/immunologyABSTRACT
INTRODUCTION: TNF-α is a pro-inflammatory cytokine known to a have a key role in the pathogenesis of chronic immune-mediated diseases. TNF-α inhibitors can be administered either as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) to treat chronic immune-mediated diseases. AREAS COVERED: Patients receiving TNF-α inhibitors are at high risk of infections. Based on our experience, in this paper, we discuss the risk of infections associated with the administration of TNF-α inhibitors and the strategies for mitigating against the development of these serious adverse events. EXPERT OPINION: Infliximab more so than etanercept appears to be responsible for the increased risk of infections. Re-activation of latent tuberculosis (LTB) infection and the overall risk of opportunistic infections should be considered before beginning TNF-α inhibitor therapy. A careful medical history, Mantoux test and chest-x-ray should always be performed before prescribing TNF-α inhibitors. Particular attention should be paid to risk factors for Pneumocystis jirovecii infection. Hepatitis B and C virological follow-up should be considered during TNF-α inhibitor treatment. Finally, patients who are at high risk of herpes zoster (HZ) reactivation would benefit from a second vaccination in adulthood when receiving TNF-α inhibitors.
Subject(s)
Immunologic Factors/adverse effects , Infections/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Etanercept/administration & dosage , Etanercept/adverse effects , Humans , Immune System Diseases/drug therapy , Immunologic Factors/administration & dosage , Infections/epidemiology , Infliximab/administration & dosage , Infliximab/adverse effects , Risk FactorsABSTRACT
INTRODUCTION: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are well tolerated in large, randomized, controlled clinical trials. However, a substantial proportion of patients do not respond to these agents and potential adverse drug reactions may be associated with its use. AREAS COVERED: Pharmacogenetics has the potential of increasing drug efficiency by identifying genetic factors responsible for lack of response or toxicities to TNF-α inhibitors. In this review, we analyze the influence of several polymorphisms upon the efficacy and safety of TNF-α inhibitors. EXPERT OPINION: Several polymorphisms have been proven to influence the response to etanercept. Among them, single nucleotide polymorphisms (SNPs) -308 G/G, -857 C/T, +489 GG and GA, HLA-DRB1-encoding SE (allele *0404 and allele *0101) favor the response to etanercept, whereas SNP -308 A/A and TNFR1A AA decrease the response. Large clinical studies are needed to confirm the relevance of these associations in order to tailor treatment and to decrease unnecessary toxicity.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Immunoglobulin G/therapeutic use , Pharmacogenetics , Polymorphism, Single Nucleotide , Receptors, Tumor Necrosis Factor/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Animals , Etanercept , Humans , Patient Selection , Phenotype , Precision MedicineABSTRACT
Systemic sclerosis (SSc) is a rare connective tissue disease characterized by chronic inflammation and fibrosis of the skin, vascular abnormalities and variable involvement of organs. TNF-α has a central role in initial host response to infections and in the pathogenesis of various systemic immune-mediated diseases. Serum levels of TNF-α are elevated in patients with SSc and favor the development of pulmonary fibrosis and pulmonary arterial hypertension. Inflammatory arthritis can occur in patients with SSc. Infliximab and etanercept may improve the inflammatory arthritis and disability in SSc. TNF-α inhibitors reduce the systemic inflammation, improve the endothelial function decreasing the risk of pulmonary arterial hypertension progression and of acute cardiovascular and/or cerebrovascular events. Physicians need to be aware of the potential risks of tuberculosis reactivation and opportunistic infections. Randomized controlled trials with TNF-α inhibitors in patients with SSc are needed to confirm the potential role of these agents in the treatment of SSc.
Subject(s)
Antirheumatic Agents/therapeutic use , Immunosuppressive Agents/therapeutic use , Scleroderma, Systemic/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Neutralizing/biosynthesis , Antirheumatic Agents/adverse effects , Antirheumatic Agents/pharmacology , Arthritis/etiology , Arthritis/prevention & control , Certolizumab Pegol , Drug Evaluation , Drug Therapy, Combination , Endothelium, Vascular/physiopathology , Etanercept , Forecasting , Humans , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/prevention & control , Immunoglobulin Fab Fragments/adverse effects , Immunoglobulin Fab Fragments/pharmacology , Immunoglobulin Fab Fragments/therapeutic use , Immunoglobulin G/adverse effects , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacology , Infliximab , Latent Tuberculosis/complications , Latent Tuberculosis/physiopathology , Opportunistic Infections/etiology , Opportunistic Infections/prevention & control , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacology , Polyethylene Glycols/therapeutic use , Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/prevention & control , Receptors, Tumor Necrosis Factor/therapeutic use , Scleroderma, Systemic/complications , Scleroderma, Systemic/immunology , Tumor Necrosis Factor-alpha/physiologyABSTRACT
INTRODUCTION: TNF-α inhibitors have demonstrated efficacy in large, randomized controlled clinical trials either as monotherapy or in combination with other anti-inflammatory or disease-modifying antirheumatic drugs in the treatment of chronic inflammatory immune-mediated diseases. Etanercept is a fusion protein that acts as a 'decoy receptor' for TNF-α. AREAS COVERED: This paper evaluates the efficacy and safety of etanercept in patients with chronic inflammatory immune-mediated diseases. EXPERT OPINION: Etanercept was first approved for the treatment of rheumatoid arthritis (RA) and subsequently of chronic plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile RA. Etanercept as other TNF-α inhibitors, particularly infliximab, may be administered off-label to treat other chronic inflammatory immune-mediated diseases such as systemic sclerosis, Behcet disease, systemic lupus erythematosus, polymyositis, dermatomyositis and mixed connective tissue disease. Early etanercept treatment prevents joint damage and helps to avoid long-term disability in arthritis. Etanercept administered at a dose of 50 mg once weekly is effective in inducing an earlier remission of RA, and etanercept 50 mg twice weekly may favor a more rapid improvement of psoriasis and psoriatic arthritis. Etanercept and adalimumab may exert beneficial effects on lipid profile and improve endothelial dysfunction. Appropriate screening tests for latent tuberculosis, hepatitis B virus and hepatitis C virus should be performed before starting etanercept. TNF-α inhibitors including etanercept are contraindicated in patients with demyelinating diseases.
Subject(s)
Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Autoimmune Diseases/drug therapy , Immunoglobulin G/adverse effects , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Antirheumatic Agents/pharmacology , Chronic Disease , Etanercept , Humans , Immunoglobulin G/pharmacology , Immunosuppressive Agents/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
BACKGROUND: Th17 is a subset of T-helper lymphocytes that produce proinflammatory cytokines, mainly IL-17. Serum IL-17 is increased in allergic patients and relates to clinical severity. Recently, it has been reported that CD161 is a highly upregulated gene in Th17 clones and all IL-17-producing cells are contained in CD161(+) T cells. This study aimed at comparing the frequency of peripheral CD161(+) T cells in patients with allergic rhinitis (AR) and in healthy controls and at relating CD161 expression with symptom severity. METHODS: Forty-four patients with AR and 29 healthy non-allergic subjects were evaluated. CD161 expression was evaluated on CD3(+), CD4(+) and CD8(+) cells by double immunofluorescence staining and fluorescence activated cell sorter analysis. Symptom severity was assessed by the Visual Analogue Scale. RESULTS: Allergic patients showed a significantly higher frequency of CD3(+)CD161(+), CD4(+)CD161(+) and CD8(+)CD161(+) cells than healthy non-allergic subjects (p < 0.0001). Moreover, the expression of CD161 cells was significantly related to clinical severity. CONCLUSIONS: This study provides evidence that a higher frequency of CD161(+) T cells is present in the peripheral blood of AR patients.